Format

Send to

Choose Destination
World J Gastroenterol. 2016 Jan 14;22(2):790-800. doi: 10.3748/wjg.v22.i2.790.

Advances in cryoablation for pancreatic cancer.

Author information

1
Xiao-Mei Luo, Medical College, Jinan University, Guangzhou 510632, Guangdong Province, China.

Abstract

Pancreatic carcinoma is a common cancer of the digestive system with a poor prognosis. It is characterized by insidious onset, rapid progression, a high degree of malignancy and early metastasis. At present, radical surgery is considered the only curative option for treatment, however, the majority of patients with pancreatic cancer are diagnosed too late to undergo surgery. The sensitivity of pancreatic cancer to chemotherapy or radiotherapy is also poor. As a result, there is no standard treatment for patients with advanced pancreatic cancer. Cryoablation is generally considered to be an effective palliative treatment for pancreatic cancer. It has the advantages of minimal invasion and improved targeting, and is potentially safe with less pain to the patients. It is especially suitable in patients with unresectable pancreatic cancer. However, our initial findings suggest that cryotherapy combined with 125-iodine seed implantation, immunotherapy or various other treatments for advanced pancreatic cancer can improve survival in patients with unresectable or metastatic pancreatic cancer. Although these findings require further in-depth study, the initial results are encouraging. This paper reviews the safety and efficacy of cryoablation, including combined approaches, in the treatment of pancreatic cancer.

KEYWORDS:

Combination therapy; Cryoablation; Cryoimmunotherapy; Pancreatic cancer

PMID:
26811625
PMCID:
PMC4716077
DOI:
10.3748/wjg.v22.i2.790
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center